ORZORA
NCT02476968
JCP023
To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)
Status:
Closed to Accrual
IV
Phase
2nd+
Line of Therapy
Relapsed / Recurrent / Refractory
Disease Stage
Biomarker(s)
BRCA1/2
Investigational
Product
Olaparib
PARP inhibitor (p.o.)
Treatment Arms
o Olaparib